



## Financial Tear Sheet

### CORPORATE PROFILE

Oncobiologics is a clinical stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics. Our current focus is on technically challenging and commercially attractive monoclonal antibodies (mAbs), in the disease areas of immunology and oncology. Our strategy is to leverage our BioSymphony™ Platform to cost-effectively develop these biosimilars on an accelerated timeline, which is fundamental to our success and we believe positions us to be a leading biosimilar company.

### PRIMARY IR CONTACT

**RussoPartners/LLC**

Alex Fudukidis

Phone: (646) 942-5632

E-mail:


[alex.fudukidis@russopartnersllc.com](mailto:alex.fudukidis@russopartnersllc.com)

### STOCK PERFORMANCE

#### ONS (Share)

<b>Exchange</b>	NASDAQ (US Dollar)
<b>Price</b>	\$1.37
<b>Change (%)</b>	▲ 0.11 (8.73%)
<b>Volume</b>	230,298
<b>Today's Open</b>	\$1.27
<b>Previous Close</b>	\$1.26
<b>Intraday High</b>	\$1.39
<b>Intraday Low</b>	\$1.26
<b>52 Week High</b>	\$3.97
<b>52 Week Low</b>	\$0.78

Data as of 11/17/17 3:58 p.m. ET



## LATEST NEWS

October 31, 2017

Oncobiologics Announces Closing Of Strategic Partnership Deal With GMS Tenshi Holdings

---

September 08, 2017

Oncobiologics Announces Strategic Partnership With GMS Tenshi Holdings Pte. Limited

---

June 01, 2017

Oncobiologics Closes On Final Portion Of \$15 Million Senior Secured Note And Warrant Offering

---

## UPCOMING EVENTS

There are currently no events scheduled.

## SEC FILINGS

Filing Date	Form
11/02/17	4
11/02/17	4
11/02/17	4
11/02/17	4

Data provided by Nasdaq. Minimum 15 minutes delayed.